The following was originally published in Volume 25, Number 9, pages 1441–1451 (DOI: https://doi.org/10.3727/096504017X14926854178616). Information shown in Table 1 appeared incorrectly as (mM) ± SE in the column headings. The correct information should have appeared as (μM ± SE). The file available online has been corrected and the corrected Table 1 is shown below.
Table 1.
Inhibitory Effects of HYDAMTIQ and Olaparib on Cell Growth of Tumor Cell Lines With Different BRCA1/2 Mutational Status After 72, 144, and 240 h of Exposure
| HYDAMTIQ, IC50 (μM ± SE) | Olaparib, IC50 (μM ± SE) | |||||
|---|---|---|---|---|---|---|
| 72 h | 144 h | 240 h | 72 h | 144 h | 240 h | |
| CAPAN-1 | 16.8 ± 0.3 | 5.4 ± 0.1 | 1.9 ± 0.1 | 9.4 ± 0.8 | 2.4 ± 0.1 | 1.9 ± 0.1 |
| n | 3 | 3 | 3 | 3 | 3 | 3 |
| CAPAN-1 C2-6 | 30.2 ± 1.0 | 9.7 ± 0.8 | 4.3 ± 0.2 | 13.3 ± 0.8 | 5.6 ± 0.2 | 4.4 ± 0.3 |
| r | 1.8 | 1.8 | 2.3 | 1.4 | 2.4 | 2.4 |
| n | 3 | 3 | 3 | 3 | 3 | 3 |
| p | 0.002 | 0.037 | 0.002 | 0.146 | 0.0010 | 0.011 |
| CAPAN-1 C2-12 | 33.7 ± 1.3 | 11.6 ± 1.0 | 4.5 ± 0.1 | 15.1 ± 0.3 | 7.7 ± 0.2 | 4.3 ± 0.1 |
| r | 2.0 | 2.1 | 2.4 | 1.6 | 3.3 | 2.3 |
| n | 3 | 3 | 3 | 3 | 3 | 3 |
| p | 0.002 | 0.023 | 0.001 | 0.016 | 0.0001 | 0.0006 |
| CAPAN-1 C2-14 | 34.5 ± 1.0 | 9.7 ± 0.4 | 3.9 ± 0.1 | 18.5 ± 2.0 | 7.6 ± 0.2 | 3.1 ± 0.2 |
| r | 2.1 | 1.8 | 2.0 | 1.5 | 2.9 | 1.8 |
| n | 3 | 3 | 3 | 3 | 3 | 3 |
| p | 0.001 | 0.004 | 0.001 | 0.004 | <0.0001 | 0.042 |
| MCF-7 | 44.7 ± 2.6 | 30.4 ± 3.4 | 8.3 ± 0.9 | 26.1 ± 0.6 | 19.9 ± 0.9 | 3.3 ± 0.3 |
| r | 2.7 | 5.6 | 4.4 | 2.8 | 8.4 | 1.8 |
| n | 4 | 4 | 3 | 4 | 4 | 3 |
| p | 0.007 | 0.026 | 0.026 | 0.003 | 0.004 | 0.054 |
IC50, concentration of drug required to inhibit cell growth by 50%; SE, standard error; r, resistance index; n, number of experiments; p, HYDAMTIQ or olaparib IC50 values of CAPAN-1 cells versus CAPAN-1 clones or MCF-7 cells.